FORM 4

## **UNITED STATES SECURITIES AND EXCHANGE COMMISSION**

Washington, D.C. 20549

OMB APP	ROVAL
 OMB Number:	2225 0

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL							
OMB Number:	3235-0287						
Estimated average burden							
hours per response:	0.5						

1. Name and Address of Reporting Person*  PELLETIER SAUNDRA L						2. Issuer Name and Ticker or Trading Symbol Tracon Pharmaceuticals, Inc. [ TCON ]								cable) or	ig Pers	son(s) to Iss	ner
	(Last) (First) (Middle) C/O TRACON PHARMACEUTICALS, INC. 4350 LA JOLLA VILLAGE DRIVE, SUITE 800					3. Date of Earliest Transaction (Month/Day/Year) 03/16/2020							below)	(give title		Other (s below)	
(Street)	(Street) SAN DIEGO CA 92122				4. If Amendment, Date of Original Filed (Month/Day/Year)							Lin	Individual or Joint/Group Filing (Check Applicable Line)     X Form filed by One Reporting Person     Form filed by More than One Reporting Person				
	Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned																
Date				. Transaction Date Month/Day/Y	Execution Date,		r, Transaction Disp Code (Instr. 5)		Dispose	urities Acquired (A) sed Of (D) (Instr. 3, 4		Benefici	es For ially (D) Following (I) (		: Direct r Indirect str. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)	
							Code	v	Amount	(A) o (D)	Price	Transac	nsaction(s) etr. 3 and 4)			(,	
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)																	
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	action (Instr.	n of E		6. Date Exercisable and Expiration Date (Month/Day/Year)			7. Title and Amount of Securities Underlying Derivative Secu (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number derivative Securities Beneficial Owned Following Reported Transactio (Instr. 4)	Owne Form ly Direct or Ind (I) (In:	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	v	(A)	(D)	Date Exercisable		opiration ate	Title	Amount or Number of Shares					
Employee Stock Option (Right to Buy)	\$1.12	03/16/2020		A		6,000		(1)	03	8/15/2030	Common Stock	6,000	\$0.00	6,000		D	

## **Explanation of Responses:**

1. The shares subject to the option shall vest and become exercisable in three equal annual installments commencing on the first anniversary of the grant date set forth in column 3 above.

## Remarks:

/s/ Scott B. Brown, Attorney-

03/18/2020

\*\* Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- \* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.